Chiron Capital Management LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD

Chiron Capital Management LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,015 shares of the biopharmaceutical company’s stock after selling 1,408 shares during the period. Chiron Capital Management LLC’s holdings in Gilead Sciences were worth $1,000,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. One Wealth Advisors LLC boosted its stake in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares during the last quarter. Ariel Investments LLC raised its stake in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Simplify Asset Management Inc. boosted its stake in shares of Gilead Sciences by 148.6% in the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after buying an additional 31,618 shares during the period. Sivik Global Healthcare LLC lifted its stake in Gilead Sciences by 25.0% in the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Wealth Management Associates Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth $255,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $122.85, for a total value of $6,590,411.10. Following the transaction, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 94,646 shares of company stock worth $11,311,286. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on GILD shares. Needham & Company LLC increased their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Wells Fargo & Company lifted their price objective on Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a report on Friday, October 31st. TD Cowen upped their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $129.13.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $125.02 on Monday. The firm has a fifty day moving average of $117.44 and a 200-day moving average of $112.88. The firm has a market capitalization of $155.11 billion, a P/E ratio of 24.90, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $127.68. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the previous year, the business posted $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.